Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
November 18, 2021 16:01 ET
|
Aclaris Therapeutics, Inc.
Investigational New Drug Application for ATI-2138 Allowed WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused...
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
November 03, 2021 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
November 02, 2021 07:00 ET
|
Aclaris Therapeutics, Inc.
Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021Planning to Initiate Phase 2b Trial of Zunsemetinib (ATI-450) in Moderate to Severe Rheumatoid...
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
August 27, 2021 16:01 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2021 16:01 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
August 05, 2021 07:00 ET
|
Aclaris Therapeutics, Inc.
Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the End of 2024Positive Preliminary Topline Data for Phase 2a Trial of ATI-1777 in...
Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
July 08, 2021 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Announces Pricing of Public Offering of Common Stock
June 09, 2021 19:55 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Announces Proposed Public Offering of Common Stock
June 08, 2021 16:15 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
June 08, 2021 07:00 ET
|
Aclaris Therapeutics, Inc.
ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor ApproachATI-1777 was Generally Well...